Author: Fiona Craig

Essentra (LSE:ESNT) shares surged 17.6% after the industrial components manufacturer published its half-year 2026 results ahead of the London market open, with investors responding positively to stronger revenue growth and an ambitious profitability target that exceeded market expectations.

The company reported first-half revenue of £166.10 million, representing a 9.8% increase at constant exchange rates. Growth was driven by higher sales volumes and improved pricing across all three of its operating regions: EMEA, the Americas and Asia-Pacific.

The results also demonstrated resilient profitability. Adjusted operating profit rose to £18.10 million, while adjusted net income reached £12.20 million. Essentra maintained an adjusted operating margin of 10.9% during the period, but the strongest investor reaction came after management outlined its medium-term objective of increasing the adjusted operating margin to 14% by 2028. The target provided a clearer path for future earnings growth and was widely viewed as the main driver behind the sharp share price rally.

To accompany the results announcement, the company hosted an analyst and investor presentation at the Storey Club in London’s financial district, alongside a live webcast for a broader audience. The event helped maintain investor interest and supported continued buying throughout the trading session.

Earlier this month, RWC Asset Management LLP disclosed an institutional holding in Essentra, suggesting professional investors had been building positions ahead of the earnings release. Meanwhile, broader market conditions remained relatively neutral, with mixed performance across US equity markets and modest weakness in the Nasdaq, leaving company-specific developments as the primary catalyst for the stock’s strong performance.

Overall, the combination of solid financial results, continued revenue growth and a higher medium-term margin target significantly boosted investor confidence, driving Essentra shares sharply higher.

LVMH (EU:MC) shares were expected to open between 2% and 3% lower on Tuesday after the luxury goods group released second-quarter sales figures that left investors unconvinced about the pace of recovery in its most profitable business.

The owner of brands including Louis Vuitton, Dior and Moët & Chandon reported that revenue from its Fashion & Leather Goods division rose 1% on a currency-adjusted basis to €8.90 billion ($10.12 billion). While this marked the division’s first quarter of growth in two years, the result fell short of analysts’ expectations for a 1.7% increase.

The company pointed to softer consumer spending in Europe, where tourism has been affected by the conflict involving Iran, reducing demand in one of its key luxury markets.

“All the focus was on FLG,” a trader said following the results.

Analysts at RBC said the key issue is whether the Fashion & Leather Goods business can still achieve full-year expectations despite facing more demanding year-on-year comparisons in the third quarter. The brokerage added that this would be necessary “for the stock to start working” in its assessment.

Across the group, LVMH delivered 3% organic sales growth during the quarter. However, the results did little to settle concerns over whether the luxury sector is moving convincingly beyond the downturn that has weighed on the industry over the past two years.

“Our thesis for LVMH hinges on the recovery in luxury sector performance and the group’s brands overperforming the industry in the long run,” Morningstar analysts said in a note to clients.

“So far, LVMH is still lagging peers, although trends are turning slightly more positive,” the brokerage added.

Novacyt (LSE:NCYT), the France-based molecular diagnostics specialist, reported first-half 2026 revenue of £11.6 million, representing an 18% increase compared with the same period last year.

The company’s instrumentation business achieved around 30% year-on-year growth, supported by increasing customer adoption of its LightBench Discover platform. Meanwhile, the clinical diagnostics division expanded by more than 20%, driven by continued demand for its non-invasive prenatal testing solutions and sickle cell disease product portfolio.

Southern Cross Diagnostics, which Novacyt acquired in March, contributed £1.8 million in revenue during the period, providing an additional boost to the group’s overall performance.

Geographically, the company delivered solid growth across both the Americas and Asia-Pacific. Revenue in the Americas increased by more than 30%, while Asia-Pacific recorded growth of approximately 22%, with both regions benefiting from stronger instrument sales and continued demand for reproductive health products.

Novacyt is also progressing with its restructuring programme, which is expected to generate up to £4.0 million in annualised cost savings. In addition, the company anticipates receiving IVDR accreditation for its DPYD kit over the coming months, supporting the continued expansion of its diagnostics portfolio.

Man Group (LSE:MAN) shares gained nearly 6% on Tuesday after the alternative asset manager reported first-half earnings and assets under management that exceeded analyst expectations. The results were driven by record client assets, stronger-than-anticipated net inflows and a sharp recovery in performance fee income. Following the announcement, Morgan Stanley said the results suggested modest upside to current consensus earnings forecasts.

The shares rose 5.7% to 317 pence, outperforming a broadly flat FTSE 100 index. Core profit before tax increased to $297 million for the six months ended June 30, compared with $146 million a year earlier, while statutory profit climbed to $201 million from $51 million over the same period.

Core net revenue rose 41% to $853 million, supported by a 21% increase in management fee income to $627 million and more than a threefold increase in performance fees to $207 million. Diluted core earnings per share more than doubled to 19.9 cents, up from 9.7 cents in the prior-year period.

Assets under management reached a record $253.6 billion, rising from $227.6 billion at the end of 2025. The increase reflected $7.1 billion of net client inflows alongside $19.8 billion of investment gains. Man Group said it outperformed the wider alternative asset management industry for inflows, with each of its four investment product categories attracting new client capital.

Analysts at Jefferies said the group’s run-rate management fee income suggests 2026 is tracking around 2% ahead of current market expectations, although the absence of a new share buyback announcement was consistent with forecasts.

Chief Executive Robyn Grew said the results demonstrate the success of the company’s multi-year diversification strategy, highlighting record assets under management and broad-based client inflows as evidence that the business continues to strengthen. She added that Man Group will continue investing in its credit, quantitative equity and multi-strategy capabilities while expanding the use of artificial intelligence to improve productivity and client outcomes.

Morgan Stanley said it expected the results to be well received by investors, citing stronger-than-expected earnings, healthy inflows and broad contributions from performance fees across the business. The broker also pointed to improving momentum across the group’s alternative investment strategies.

The board maintained its interim dividend at 5.7 cents per share. As of July 24, the company had completed $29 million of its existing $50 million share buyback programme.

Creo Medical (LSE:CREO) reported a strong first-half performance for 2026, with revenue increasing 45% year-on-year to £3.2 million as demand for its advanced medical technology portfolio continued to grow.

The company also made further progress in improving operational efficiency, reducing operating costs by 15% during the first six months of the year. As a result, its operating loss narrowed by more than 25%, reflecting the benefits of cost-saving initiatives alongside higher sales.

Revenue growth was supported by increased adoption of key products, including Speedboat, SpydrBlade Flex and MicroBlate Fine. Creo Medical also expanded its commercial presence into new international markets, with particularly strong progress across Latin America.

Management continued to streamline the business by scaling its commercial platform, simplifying operations and outsourcing manufacturing activities, helping to create a leaner operating model while supporting future growth.

The company reaffirmed its full-year revenue growth guidance of between 50% and 60%. Management said a healthy order book, together with revenue expected to be weighted toward the second half of the year, provides confidence in achieving that target. Creo Medical also believes its lower cost base and recent financing activities will support its progress towards profitability.

Unite Group (LSE:UTG) reported a 2% year-on-year decline in adjusted net income for the first half of 2026, with higher financing costs and the impact of previous asset disposals weighing on earnings during the period.

The student accommodation provider generated adjusted net income of £142 million, while reporting an IFRS pretax loss of £417.10 million. The statutory loss was primarily driven by a 6.4% reduction in the value of its property portfolio during the first half.

Management said adjusted earnings were affected by increased interest expenses, the effect of properties sold during 2025 and slightly lower occupancy levels. Adjusted earnings per share declined 8%, reflecting initial dual-running costs associated with the acquisition of Empiric Student Property as well as the impact of a larger share count.

During the period, Unite completed £165 million of share buybacks and disposed of £130 million of assets as part of its ongoing capital management strategy. The company reported EPRA net tangible assets per share of £8.65 and a net asset value per share of £8.79.

Despite the softer first-half performance, Unite maintained its full-year 2026 adjusted earnings per share guidance of between 41.5p and 43.0p. The group expects occupancy levels of 94% to 96% and rental growth of between 1% and 2% for the 2026/27 academic year.

The company said demand remains strong at the UK’s leading universities, supported by a continued shortage of purpose-built student accommodation. Improved reservation trends and targeted sales initiatives have also contributed to encouraging leasing activity ahead of the 2026/27 academic year.

Coats Group (LSE:COA) reported first-half revenue of $837 million, an increase of 19% compared with the same period last year. On an organic basis, revenue grew 1%, reflecting resilient underlying performance despite softer conditions in several of its end markets.

The company maintained an adjusted EBIT margin of 19.8% during the period as disciplined cost management and procurement efficiencies helped offset higher investment in strategic growth initiatives. Adjusted basic earnings per share declined 6% year-on-year to $0.04, primarily reflecting increased spending on technology and long-term business expansion.

Coats continued to outperform its core apparel and footwear markets, gaining market share even as those sectors contracted by mid-single digits during the first half. Management attributed this performance to ongoing product innovation, operational flexibility and strong customer relationships. Additional revenue growth was generated through expansion into adjacent markets and the launch of new products, including composite energy tapes and digital solutions.

Adjusted operating profit reached $166 million during the first six months of the year, while adjusted net debt stood at $842 million. The company reaffirmed its full-year guidance and expects apparel and footwear markets to remain modestly weaker during the second half. Coats also anticipates delivering around $15 million in additional cost savings over the remainder of the year, including synergies from the OrthoLite acquisition. Management expects strong free cash flow generation for the full year, supporting its long-term objective of delivering $1 billion in cumulative free cash flow over five years.